Physician profile
Michael A Selva
NPI 1164450581
$2,815.88
in general payments reported to CMS, 2019-2025
17 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 85% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $201 · 2021: $229 · 2022: $235 · 2023: $289 · 2024: $394 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484 · Travel and Lodging: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.26 |
| Travel and Lodging | $409.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $1,039.54 | 2023-2025 | Illuccix |
| Janssen Biotech, INC. | $373.43 | 2020-2025 | Rybrevant, Carvykti |
| Blue Earth Diagnostics | $334.52 | 2019-2025 | Posluma |
| Tactile Systems Technology INC | $182.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $165.99 | 2023-2025 | |
| Pfizer INC. | $129.31 | 2022 | |
| Astellas Pharma US INC | $124.99 | 2024 | Xtandi |
| Siemens Medical Solutions USA, INC. | $80.03 | 2021-2024 | Truebeam |
| Merck Sharp & Dohme LLC | $73.91 | 2019 | |
| Myriad Genetic Laboratories, INC. | $72.86 | 2023 | Prolaris |
| Gt Medical Technologies, INC | $71.09 | 2024 | Gammatile |
| Bayer Healthcare Pharmaceuticals INC. | $65.93 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $24.09 | 2024 | Orgovyx |
| Emd Serono, INC. | $23.17 | 2022 | |
| Accuray Incorporated | $20.17 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $19.76 | 2022 | |
| Amgen INC. | $15.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Selva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.